Eligard Exposure

PreclinicalSmall molecule

Astellas

Eligard Exposure is one of 38 small molecule programs targeting Prostate Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Prostate CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

1 3

Ritalin

Farxiga

Jevtana

Balversa

Estrace

Lynparza

Lupron

Sun Pharmaceutical Industries, Inc.

Xtandi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Carcinoma1 trial

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Completed· Astellas logo

Astellas··NCT02128334·645 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eligard Exposure. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eligard Exposure compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eligard Exposure. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

Eligard Exposure

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News